Objectives
This study will be conducted in two parts.
Phase 1b is dose escalation in which patients are tested with SD-101 at various doses in
combination with 200 mg pembrolizumab in patients with metastatic melanoma.
Phase 2 will consist of 4 expansion cohorts to evaluate the efficacy and safety of SD-101
given in combination with 200 mg pembrolizumab in specific melanoma populations and
recurrent or metastatic HNSCC.